Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.
Lucia H Lee, Milan S Blake
Index: Clin. Vaccine Immunol. 19(4) , 551-6, (2012)
Full Text: HTML
Abstract
New multivalent CRM(197)-based conjugate vaccines are available for childhood immunization. Clinical studies were reviewed to assess meningococcal group C (MenC) antibody responses following MenC-CRM(197) coadministration with CRM(197)-based pneumococcal or Haemophilus influenzae type b conjugate vaccines. Infants receiving a total CRM(197) carrier protein dose of ∼50 μg and concomitant diphtheria-tetanus-acellular pertussis (DTaP)-containing vaccine tended to have lower MenC geometric mean antibody titers and continued to have low titers after the toddler dose. Nevertheless, at least 95% of children in the reported studies achieved a MenC serum bactericidal antibody (SBA) titer of ≥ 1:8 after the last infant or toddler dose. SBA was measured using an assay with a baby rabbit or human complement source. Additional studies are needed to assess long-term antibody persistence and MenC CRM(197) conjugate vaccine immunogenicity using alternative dosing schedules.
Related Compounds
Related Articles:
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.
2013-02-12
[Proc. Natl. Acad. Sci. U. S. A. 110(7) , 2517-22, (2013)]
Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.
2011-11-01
[Expert Rev. Vaccines 10(11) , 1621-31, (2011)]
Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
2011-07-01
[Anticancer Res. 31(7) , 2483-8, (2011)]
2012-09-21
[Vaccine 30(43) , 6111-4, (2012)]
2012-01-01
[Anticancer Drugs 23(1) , 81-9, (2012)]